Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
Abstract Aims Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a s...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-04-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13239 |
| _version_ | 1819120573698015232 |
|---|---|
| author | Kazuki Kagami Hiroaki Sunaga Hidemi Sorimachi Tomonari Harada Kuniko Yoshida Toshimitsu Kato Koji Kurosawa Ryo Kawakami Norimichi Koitabashi Tatsuya Iso Takeshi Adachi Masahiko Kurabayashi Masaru Obokata |
| author_facet | Kazuki Kagami Hiroaki Sunaga Hidemi Sorimachi Tomonari Harada Kuniko Yoshida Toshimitsu Kato Koji Kurosawa Ryo Kawakami Norimichi Koitabashi Tatsuya Iso Takeshi Adachi Masahiko Kurabayashi Masaru Obokata |
| author_sort | Kazuki Kagami |
| collection | DOAJ |
| description | Abstract Aims Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF. Methods and results Measurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospectively followed‐up for a composite outcome of all‐cause mortality or HF hospitalization. Compared with control subjects, levels of FABP1 were elevated in HF patients [7.9 (6.4–11.7) vs. 17.6 (10.4–28.9) ng/mL, P < 0.0001]. There were significant correlations between FABP1 levels and estimated right ventricular systolic pressure and right atrial pressure. During a median follow‐up of 12.0 months, there were 55 primary composite endpoints in the HF cohort. The highest FABP1 tertile was associated with a three‐fold increased risk of the composite outcome compared with the lowest tertile [95% confidence interval (1.46–6.68), P = 0.003], but other conventional hepatobiliary markers did not predict the outcome. After adjusting for age, sex, atrial fibrillation, and N‐terminal pro‐B‐type natriuretic peptide levels, serum FABP1 remained independently associated with the outcome. Adding FABP1 to the model based on clinical factors and N‐terminal pro‐B‐type natriuretic peptide significantly improved the prognostic value (global χ2 20.8 vs. 15.5, P = 0.01). Conclusion Serum FABP1 levels are elevated in compensated HF patients, and the magnitude of elevation is independently associated with pulmonary hypertension, right atrial hypertension, and worse clinical outcomes. FABP1 may serve as a new potential biomarker for the assessment of hitherto unrecognized derangement of cardio‐hepatic interaction in HF. |
| first_indexed | 2024-12-22T06:22:49Z |
| format | Article |
| id | doaj.art-2c5e73a491e7436a99b91f63ed4fb4f6 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-12-22T06:22:49Z |
| publishDate | 2021-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-2c5e73a491e7436a99b91f63ed4fb4f62022-12-21T18:35:55ZengWileyESC Heart Failure2055-58222021-04-01821494150110.1002/ehf2.13239Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failureKazuki Kagami0Hiroaki Sunaga1Hidemi Sorimachi2Tomonari Harada3Kuniko Yoshida4Toshimitsu Kato5Koji Kurosawa6Ryo Kawakami7Norimichi Koitabashi8Tatsuya Iso9Takeshi Adachi10Masahiko Kurabayashi11Masaru Obokata12Department of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDivision of Cardiology National Defense Medical College Tokorozawa Saitama JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanDepartment of Cardiovascular Medicine Gunma University Graduate School of Medicine 3‐39‐22 Showa‐machi Maebashi Gunma 371‐8511 JapanAbstract Aims Few biomarkers to evaluate pathophysiological changes in extra‐cardiac tissues have been identified in patients with heart failure (HF). Fatty acid‐binding protein 1 (FABP), also known as liver FABP, is predominantly expressed in the liver. Circulating FABP1 has been proposed to be a sensitive biomarker for liver injury. However, little is known about the potential role of FABP1 as a biomarker for HF. Methods and results Measurements of serum FABP1 and echocardiography were performed in subjects with compensated HF (n = 162) and control subjects without HF (n = 20). Patients were prospectively followed‐up for a composite outcome of all‐cause mortality or HF hospitalization. Compared with control subjects, levels of FABP1 were elevated in HF patients [7.9 (6.4–11.7) vs. 17.6 (10.4–28.9) ng/mL, P < 0.0001]. There were significant correlations between FABP1 levels and estimated right ventricular systolic pressure and right atrial pressure. During a median follow‐up of 12.0 months, there were 55 primary composite endpoints in the HF cohort. The highest FABP1 tertile was associated with a three‐fold increased risk of the composite outcome compared with the lowest tertile [95% confidence interval (1.46–6.68), P = 0.003], but other conventional hepatobiliary markers did not predict the outcome. After adjusting for age, sex, atrial fibrillation, and N‐terminal pro‐B‐type natriuretic peptide levels, serum FABP1 remained independently associated with the outcome. Adding FABP1 to the model based on clinical factors and N‐terminal pro‐B‐type natriuretic peptide significantly improved the prognostic value (global χ2 20.8 vs. 15.5, P = 0.01). Conclusion Serum FABP1 levels are elevated in compensated HF patients, and the magnitude of elevation is independently associated with pulmonary hypertension, right atrial hypertension, and worse clinical outcomes. FABP1 may serve as a new potential biomarker for the assessment of hitherto unrecognized derangement of cardio‐hepatic interaction in HF.https://doi.org/10.1002/ehf2.13239Heart failureFatty acid‐binding proteinBiomarkersCardio‐hepatic interaction |
| spellingShingle | Kazuki Kagami Hiroaki Sunaga Hidemi Sorimachi Tomonari Harada Kuniko Yoshida Toshimitsu Kato Koji Kurosawa Ryo Kawakami Norimichi Koitabashi Tatsuya Iso Takeshi Adachi Masahiko Kurabayashi Masaru Obokata Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure ESC Heart Failure Heart failure Fatty acid‐binding protein Biomarkers Cardio‐hepatic interaction |
| title | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
| title_full | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
| title_fullStr | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
| title_full_unstemmed | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
| title_short | Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure |
| title_sort | prognostic impact of elevated fatty acid binding protein 1 in patients with heart failure |
| topic | Heart failure Fatty acid‐binding protein Biomarkers Cardio‐hepatic interaction |
| url | https://doi.org/10.1002/ehf2.13239 |
| work_keys_str_mv | AT kazukikagami prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT hiroakisunaga prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT hidemisorimachi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT tomonariharada prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT kunikoyoshida prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT toshimitsukato prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT kojikurosawa prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT ryokawakami prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT norimichikoitabashi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT tatsuyaiso prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT takeshiadachi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT masahikokurabayashi prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure AT masaruobokata prognosticimpactofelevatedfattyacidbindingprotein1inpatientswithheartfailure |